NOBILITY (2022) — Trial Summary
NOBILITY (2022): The NOBILITY trial evaluated obinutuzumab, a type II anti-CD20 monoclonal antibody, for the treatment of proliferative lupus nephritis in combination with standard therapy.
References
- Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100-107.